Cascade‐Responsive Nanoprodrug Disrupts Immune‐Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202500176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Xin Guan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, P. R. China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Immunotherapy, Prodrugs, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Pilot Medical Construction Project of Fudan University.
Abstract (Originalsprache)
The abnormal tumor mechanical microenvironment due to specific cancer‐associated fibroblasts (CAFs) subset and low tumor immunogenicity caused by inefficient conversion of active chemotherapeutic agents are two key obstacles that impede patients with desmoplastic tumors from achieving stable and complete immune responses. Herein, it is demonstrated that FAP‐α + CAFs‐induced stromal stiffness accelerated tumor progression by precluding cytotoxic T lymphocytes. Subsequently, a cascade‐responsive nanoprodrug capable of re‐educating FAP‐α + CAFs and amplifying tumor immunogenicity for potentiated cancer mechanoimmunotherapy is ingeniously designed. Benefiting from the active targeted release of angiotensin II receptor antagonist (losartan) guided by FAP‐α cleavable peptide and the efficient conversion of topoisomerase I inhibitor (7‐Ethyl‐10‐hydroxycamptothecin) prodrug under high glutathione/esterase within tumor cells, this regimen created an immune‐activated landscape that retarded primary tumor growth and counteracted resistance to immune checkpoint inhibitor in mice with triple‐negative breast cancer. This nanoprodrug‐assisted mechanoimmunotherapy can serve as a universal strategy for conferring efficient tumoricidal immunity in “immune excluded” desmoplastic tumor interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, P. R. China.
- Department of Ultrasound, Institiute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
- Department of Ultrasound, Zhejiang Hospital, Hangzhou, 310013, P. R. China.
- Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
ORCID-Profile: Huixiong Xu
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Pilot Medical Construction Project of Fudan University
- Scientific Research and Development Fund of Zhongshan Hospital of Fudan University
Zitieren
APA
Guan, X., Shen, Y., Zhao, C., Li, X., Li, X., Lu, D., Wang, L., Liu, L., Wu, S., Huang, B., Guo, L., & Xu, H. (2025). Cascade‐Responsive Nanoprodrug Disrupts Immune‐Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500176
Vancouver
Guan X, Shen Y, Zhao C, Li X, Li X, Lu D, et al. Cascade‐Responsive Nanoprodrug Disrupts Immune‐Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500176
BibTeX
@article{Guan2025,
author = {Guan, Xin and Shen, Yuting and Zhao, Chongke and Li, Xiao and Li, Xiaolong and Lu, Dan and Wang, Lifan and Liu, Linna and Wu, Shengbo and Huang, Bin and Guo, Lehang and Xu, Huixiong},
title = {Cascade‐Responsive Nanoprodrug Disrupts Immune‐Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202500176}
}
EUVIMED